(P-127) Safety and Efficacy of Fecal Microbiota Spores, Live-brpk (Formerly SER-109) in Patients with Recurrent Clostridioides difficile Infection (CDI): Subgroup Analysis by Number of Prior CDI Recurrences from an Integrated Analysis of Phase 3 Trials

Director of Infectious Diseases Research
Corewell Health William Beaumont University Hospital, Oakland University William Beaumont School of Medicine
Royal Oak, Michigan, United States

Associate Professor
Emory University
Atlanta, GA, United States

Sutter Health Research Enterprise
San Jose, California, United States

Seres Therapeutics
Cambridge, Massachusetts, United States

Seres Therapeutics, Cambridge, MA
Cambridge, Massachusetts, United States

Nestlé Health Science
Vevey, Vaud, Switzerland

Professor of Medicine
Mayo Clinic
Rochester, MN, United States